|
Powered by Cell Signaling Technology |
Site Information |
---|
GAVEAsFkCCsGAII SwissProt Entrez-Gene |
Blast this site against: NCBI SwissProt PDB |
Site Group ID: 9263579 |
Available spectra: 2 CST |
In vivo Characterization | |
---|---|
Methods used to characterize site in vivo: | |
Disease tissue studied: | |
Relevant cell line - cell type - tissue: |
References | |
---|---|
Rikova K (2013) CST Curation Set: 20219; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Rikova K (2013) CST Curation Set: 20220; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Rikova K (2013) CST Curation Set: 20215; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Rikova K (2013) CST Curation Set: 20216; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Rikova K (2013) CST Curation Set: 18854; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Rikova K (2012) CST Curation Set: 16030; Year: 2012; Biosample/Treatment: cell line, MKN45/crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Rikova K (2012) CST Curation Set: 16031; Year: 2012; Biosample/Treatment: cell line, H3255/iressa; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Rikova K (2012) CST Curation Set: 16032; Year: 2012; Biosample/Treatment: cell line, H1703/gleevec; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Possemato A (2009) CST Curation Set: 8176; Year: 2009; Biosample/Treatment: cell line, HCT116/untreated & calyculin_A; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Possemato A (2009) CST Curation Set: 8175; Year: 2009; Biosample/Treatment: cell line, HCT116/untreated & calyculin_A; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Possemato A (2009) CST Curation Set: 8143; Year: 2009; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Rikova K (2007) CST Curation Set: 3513; Year: 2007; Biosample/Treatment: cell line, 786-0 VHL-30/untreated; Disease: kidney cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |